What is Thalidomide?

Category: Prescription Drugs

Most popular types: Thalomid


See also: Bortezomib-thalidomide Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide (VTD-PACE) Bortezomib-thalidomide-dexamethasone (VTd) Dexamethasone-thalidomide-cisplatin-doxorubicin-cyclophosphamide-etoposide (DT-PACE) Melphalan-prednisone-thalidomide (MPT) RT protocol Thalidomide-dexamethasone (Td) Thalidomide-prednisone

Thalidomide is an immunosuppressant agent that may be used for the treatment of multiple myeloma. It is often used in combination with other agents, but it may also be used alone as a maintenance or salvage treatment.

Reported purpose & perceived effectiveness
Purpose Patients Evaluations Perceived Effectiveness
Multiple myeloma 3 1
Discoid lupus erythematosus 1 1
Myelofibrosis 1 1
Prurigo nodularis 1 1

  • Major
  • Moderate
  • Slight
  • None
  • Can't tell

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations

Commonly reported side effects and conditions associated with Thalidomide

Side effect Patients
Neuropathy 2
Excessive daytime sleepiness (somnolence) 1
Nephronophthisis 1
Nerve damage 1


Based on patients currently taking Thalidomide

Dosage Patients
50 mg daily 1

Why patients stopped taking Thalidomide

Multiple reasons could be selected

Reason Patients
Course of treatment ended 2
Side effects too severe 1
See all 3 patients who've stopped taking Thalidomide


Currently taking Thalidomide

Duration Patients
2 - 5 years 1

Stopped taking Thalidomide

Duration Patients
1 - 6 months 1
6 months - 1 year 2
Adherence Evaluations
Always 4
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden Evaluations
Very hard to take 1
Somewhat hard to take 1
A little hard to take 0
Not at all hard to take 2

What people switch to and from

Patients started taking Thalidomide after stopping:

Treatment Patients
Hydrocortisone topical (Cortizone-10) 1
Hydroxyurea (Hydrea) 1
Last updated:
There are no evaluations for Thalidomide.